Company / Net Income
Axsome Therapeutics, Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$183.2M
FY2025
5-year range
-$287.2M / -$130.4M
FY2021-FY2025
Trend
+36.2%
vs FY2024
Sector context
#150 of 216
Health Care
What the data says
At -$183M, Axsome Therapeutics, Inc.'s net income ranks #150 of 216 in the Health Care sector. Net Income returned to growth in FY2025 after 8 years of decline, reaching -$183M.
Based on SEC 10-K filings.
-$183M in FY2025.
Improved from -$239M to -$183M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#150 of 216 in Health CareTop 69% of 216This company -$183.2M Sector average $454.3M
▼
-140.3% below sector average
Key checks
Key Insights
- In FY2025, net income increased 36.2% year-over-year.
- Ranks #150 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$183.2M | +36.2% |
| FY2024 | -$287.2M | -20.1% |
| FY2023 | -$239.2M | -27.8% |
| FY2022 | -$187.1M | -43.5% |
| FY2021 | -$130.4M | -26.7% |
| FY2020 | -$102.9M | -50.6% |
| FY2019 | -$68.3M | -120.7% |
| FY2018 | -$31.0M | -7.0% |
| FY2017 | -$28.9M | -6.4% |
| FY2016 | -$27.2M | -122.8% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026